Stockscreener 앱 받기
0.9505
0.41%
-0.0039
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics (IRD) Reveals Promising Gene Therapy Trial Results | IRD Stock News - GuruFocus
Opus Genetics Announces Presentation of OPGX-LCA5 Gene - GlobeNewswire
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline - Yahoo Finance
Opus Genetics shareholders approve key proposals By Investing.com - Investing.com Nigeria
Opus Genetics shareholders approve key proposals - Investing.com Australia
Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 - marketscreener.com
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath - markets.businessinsider.com
Opus Genetics (NASDAQ:IRD) Research Coverage Started at Craig Hallum - Defense World
Opus Genetics (IRD) Receives Buy Rating with Promising Gene Ther - GuruFocus
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns - The Manila Times
Drug company founder pulls plug on proxy fight at her former company - Crain's Detroit Business
Craig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
Mina Sooch Issues Open Letter To Opus Genetics' Stockholders - marketscreener.com
Night Vision Disturbances Market to Reach New Heights in Growth - openPR.com
Night Vision Disturbances Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris - The Globe and Mail
Opus Genetics says Mina Sooch Determined To Withdraw Her Slate Of Nominees For Election To Board - MarketScreener
Opus Genetics issues 1-month pediatric gene therapy results - Optometry Times
Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch - simplywall.st
Opus Genetics reports 1-month pediatric results in gene therapy for inherited retinal disease - Ophthalmology Times
Opus Genetics reports early success in pediatric gene therapy trial - Investing.com
Opus Genetics reports early success in pediatric gene therapy trial By Investing.com - Investing.com India
Opus Genetics Announces One-Month Clinical Data from - GlobeNewswire
Breakthrough: New Gene Therapy Restores Vision in 16-Year-Old Patient Clinical Trial - Stock Titan
Rexahn Pharmaceuticals stock hits 52-week low at $0.81 By Investing.com - Investing.com South Africa
Rexahn Pharmaceuticals stock hits 52-week low at $0.81 - Investing.com
Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress - The Manila Times
Opus Genetics Files Definitive Proxy Statement and Sends - GlobeNewswire
Opus Genetics' Future at Stake: Ex-CEO Challenges $21.5M-Backed Gene Therapy Transformation - Stock Titan
Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts - Yahoo Finance
Opus Genetics Terminates Purchase Agreement with Lincoln Park - TipRanks
Opus Genetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Opus Genetics to Participate in Upcoming Investor Conference in April - GlobeNewswire
Exclusive Ophthalmology Gene Therapy Updates: Opus Genetics CEO Takes Center Stage at RBC Conference - Stock Titan
Opus Genetics (NASDAQ:IRD) Receives Buy Rating from HC Wainwright - Defense World
Opus Genetics (NASDAQ:IRD) Price Target Cut to $8.00 by Analysts at Jones Trading - Defense World
Opus Genetics price target lowered to $8 from $9 at JonesResearch - TipRanks
H.C. Wainwright maintains $8 target on Opus Genetics stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $8 target on Opus Genetics stock - Investing.com
Opus Genetics Announces Full Year 2024 Financial Results, Provides Corporate Update - VisionMonday.com
Opus Genetics earnings missed by $1.22, revenue fell short of estimates - Investing.com Canada
Opus Leans Lower on Year-End Figures - Baystreet.ca
Opus Genetics Announces Financial Results for Full Year 2024 - TradingView
Opus Genetics Transformation: $51.8M Cash Position Powers 4 Clinical Readouts in 2025 - Stock Titan
Ousted founder of drug development company tries to take back the reins - Crain's Detroit Business
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
Pleasing Signs As A Number Of Insiders Buy Opus Genetics Stock - simplywall.st
Several Insiders Invested In Opus Genetics Flagging Positive News - Yahoo Finance
0.27%
0.30%
자본화:
|
볼륨(24시간):